Bullous pemphigoid is an autoimmune skin disease that causes large, fluid-filled blisters, most often in people over 70. It develops when the immune system mistakenly attacks proteins that hold the outer layer of skin to the tissue beneath it, causing the layers to separate and fill with fluid. The condition is the most common autoimmune blistering disorder, with an annual incidence of 2 to 23 cases per million in the general population, rising sharply to 190 to 312 cases per million in people over 80.
What Happens Inside the Skin
Your skin stays intact because of anchoring proteins at the boundary between the outer layer (epidermis) and the layer beneath it (dermis). Two of these proteins are central to bullous pemphigoid. One, called BP180, is a transmembrane protein that reaches from inside the skin cell outward, binding to structural components in the tissue below. The other, BP230, works on the inside of the cell, connecting the internal skeleton of the skin cell to its attachment point at the base.
In bullous pemphigoid, the immune system produces antibodies that target BP180 in particular. These antibodies trigger a chain of destructive events. First, they cause the skin cell to swallow its own BP180 protein, pulling it off the surface and breaking it down internally. This alone weakens the bond between the skin layers. At the same time, the antibodies recruit immune cells, especially a type of white blood cell called eosinophils, which flood into the area and release enzymes that chew through BP180 and surrounding tissue. The combination of protein loss and enzyme damage creates a gap between the epidermis and dermis, and fluid rushes in to form a blister.
Early Symptoms Before Blisters Appear
Bullous pemphigoid often doesn’t start with blisters at all. In many patients, there’s a prodromal phase where the skin becomes intensely itchy, red, or covered in hive-like patches and plaques. This phase can last weeks or even months before any blisters show up, which makes early diagnosis tricky. The itch during this stage can be severe enough to significantly affect sleep and daily life.
When the bullous phase begins, large, tense blisters appear on reddened or normal-looking skin. Unlike the fragile blisters seen in some other conditions, these are firm and don’t rupture easily. They most commonly develop on the arms, legs, and trunk. Mucosal involvement (mouth, eyes, genitals) occurs in roughly 10% to 30% of cases, which is far less common than in related conditions like pemphigus vulgaris.
How It Differs From Pemphigus Vulgaris
People sometimes confuse bullous pemphigoid with pemphigus vulgaris because both cause blisters, but the two diseases are quite different. Pemphigus vulgaris produces fragile, floppy blisters that break open almost immediately, leaving raw, painful erosions that heal slowly. It frequently starts in the mouth, and scalp involvement is seen in up to 60% of patients. The blisters form within the epidermis itself because the antibodies attack the connections between skin cells.
Bullous pemphigoid, by contrast, produces tense, durable blisters that form beneath the epidermis at the basement membrane zone. The dominant symptom is itch rather than pain, and oral involvement is much less common. Under the microscope, the distinction is clear: pemphigus vulgaris shows separation between skin cells within the epidermis, while bullous pemphigoid shows a clean split below the epidermis with eosinophils filling the blister cavity.
Who Gets It and Why
Age is the strongest risk factor. The mean age at diagnosis ranges from 66 to 83 years across different populations, and the incidence rises exponentially after 80. The reasons for this age pattern aren’t fully understood, but age-related changes in immune regulation likely play a role.
Certain medications can also trigger the condition. The drugs with the strongest evidence include:
- DPP-4 inhibitors (gliptins), a class of diabetes medications, with multiple agents in the class implicated
- PD-1/PD-L1 inhibitors, a type of cancer immunotherapy, with over 21 reported cases
- Loop diuretics, particularly furosemide, commonly prescribed for heart failure and fluid retention
- NSAIDs, including common pain relievers and aspirin
- Certain blood pressure medications, including ACE inhibitors, angiotensin receptor blockers, and calcium channel blockers
A total of 89 different drugs have been linked to drug-associated bullous pemphigoid in the medical literature. Neurological conditions, particularly dementia and Parkinson’s disease, are also well-established associations, though whether the link is the disease itself, the medications used to treat it, or shared immune mechanisms remains an open question.
How It’s Diagnosed
Clinical appearance alone isn’t enough to confirm bullous pemphigoid because several conditions can look similar. The gold standard for diagnosis is a skin biopsy from an area next to (not on) a blister, examined under a special technique called direct immunofluorescence. This test looks for a specific pattern: a thin, continuous line of antibodies (IgG) or complement proteins (C3) deposited along the boundary between the epidermis and dermis. That linear pattern at the basement membrane zone is the diagnostic hallmark.
A standard biopsy of an early blister will show the characteristic subepidermal split with eosinophils in the blister cavity and surrounding tissue. Blood tests can also detect circulating antibodies against BP180, and the level of these antibodies often correlates with disease activity.
Treatment and What to Expect
First-line treatment for most patients involves potent topical corticosteroids applied to the entire body surface, not just the blistered areas. For widespread or severe disease, oral corticosteroids or other immune-suppressing medications may be needed. The goal is to stop new blisters from forming, allow existing ones to heal, and then gradually taper treatment.
Most patients respond to treatment, but the disease tends to follow a relapsing and remitting course. Some people achieve lasting remission after months of treatment, while others require long-term low-dose therapy to stay blister-free. If a medication is suspected as the trigger, stopping it can sometimes lead to resolution, though this doesn’t always happen quickly.
A newer option showing promise is dupilumab, a biologic that blocks a specific immune signaling pathway involved in the condition. In a study of 146 patients published in JAMA Dermatology, 87% achieved disease control within four weeks, with a median time to control of just 14 days. About 36% reached complete remission during the observation period. Roughly 73% of patients reported no side effects, though infections and elevated eosinophil counts were the most common adverse events in those who did.
Prognosis and Long-Term Outlook
Bullous pemphigoid is not usually fatal on its own, but it carries meaningful risks in the elderly population it affects. A large Italian multicenter study found a 1-year mortality rate of 3.2%, rising to 18.2% at three years and 27.4% at five years. These numbers reflect the fact that patients are typically elderly with other health conditions, and that long-term immunosuppressive treatment itself carries risks, particularly infections.
For many patients, the disease eventually burns out. Some achieve complete remission within one to five years and can stop treatment. Others experience a more chronic course. The intensity of itching, the extent of blistering, and antibody levels at diagnosis all help predict how the disease will behave over time.